替加环素治疗碳青霉烯类耐药革兰阴性菌所致医院获得性肺炎和呼吸机相关性肺炎疗效观察  

作　　者：卫琦[1] 胡星 张欢 祃红原[1] 刘剑萍[1] 

机构地区：[1]四川省成都市第三人民医院重症医学科,四川成都610031

出　　处：《中国药业》2018年第A01期77-78,共2页China Pharmaceuticals

摘　　要：目的探讨替加环素治疗碳青霉烯类耐药革兰阴性菌所致医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)的临床疗效。方法选取医院2016年10月至2018年10月收治的HAP和VAP患者80例,随机均分为观察组和对照组,各40例。对照组患者采用常规抗感染治疗,观察组患者加用替加环素治疗。结果观察组临床有效率、细菌清除率分别为65.00%和57.50%,明显高于对照组的32.50%和22.50%(P<0.05)。结论替加环素治疗碳青霉烯类耐药革兰阴性菌所致HAP和VAP临床效果显著,值得临床推广。Objective To investigate the clinical efficacy of tegacycline in the treatment of hospital acquired pneumonia(HAP)and ventilator-associated pneumonia(VAP)caused by carbapenem-resistant gram-negative bacteria.Methods Totally 80 patients with HAP and VAP admitted to our hospital from October 2016 to October 2018 were selected and randomly divided into the observation group and the control group,40 cases in each group.The control group was treated with routine antiinfection therapy,while the observation group was treated with tegacycline.Results The clinical effective rate and bacterial clearance rate of the observation group were 65.00%and 57.50%,which were significantly higher than 32.50%and 22.50%of the control group(P<0.05).Conclusion Tegacycline is effective in the treatment of HAP and VAP caused by carbapenemresistant gram-negative bacteria,which is worthy of clinical promotion.

关 键 词：替加环素 碳青霉烯类 革兰阴性菌 医院获得性肺炎 呼吸机相关性肺炎 临床疗效 

分 类 号：R969.4[医药卫生—药理学]